Group 1: Research Basic Information - The research object is Mingde Bio, belonging to the medical device industry, and the reception time is June 12, 2025. The listed company's reception staff includes the chairman and general manager Chen Lili, independent director Quan Yi, board secretary, financial officer and deputy general manager Wang Rui, and Lin Shangyan, the sponsor representative of Guojin Securities Co., Ltd. [16] Group 2: Detailed Research Institutions - The reception objects are investors who participated online in the "2025 Hubei Listed Companies Investor Online Collective Reception Day Activity and 2024 Annual Performance Briefing", and the type is others [17] Group 3: Core Views - In product development, the company will base itself on competitive areas such as pathogen diagnosis, cardiovascular and cerebrovascular disease diagnosis, and infectious disease diagnosis, enrich and optimize technology platforms and product pipelines, and enhance medical informatization and third - party medical inspection service capabilities. In external investment, it has jointly established a venture capital management company with Junlian Capital and will continue to cooperate with excellent investment institutions to establish industrial funds for external development [22] - The company disclosed the "2025 Valuation Enhancement Plan" in April 2025, aiming to enhance investment value and shareholder return through measures such as improving operating efficiency, seeking investment and mergers, cash dividends, long - term incentive plans, and optimizing information disclosure and investor relations management [23] - Currently, the company has not entered the vaccine or innovative drug fields of the infectious disease industry chain. It is exploring new growth points by increasing R & D investment in in - vitro diagnostic reagents and high - end medical equipment and evaluating investment and merger opportunities [24] - The company will continue to focus on its main business in the in - vitro diagnosis field, explore new business areas such as health food, and pay attention to accounts receivable collection, with the accounts receivable balance decreasing [25] - In March 2025, the company completed the share repurchase plan that started in 2024. If there are subsequent plans, it will go through review and disclosure procedures [25] - The six - item respiratory virus nucleic acid detection kit was put on the market in May 2025, and the current sales proportion is small [26]

Group 1: Company Performance and Strategy - The company has faced poor performance in both revenue and stock price over the past two years, with significant cash reserves not being effectively utilized [2][3] - The company aims to achieve a market value of 100 billion CNY and plans to enhance operational efficiency, seek investment mergers, and maintain cash dividends as part of its 2025 valuation enhancement plan [4] - The company is focusing on core technology advantages and exploring new growth points in in vitro diagnostic reagents and high-end medical equipment [5] Group 2: Investment and Mergers - The company has established a joint venture with Junlian Capital to focus on investment and mergers in innovative healthcare [3] - There are plans to collaborate with excellent fund managers and investment institutions to create industry funds supporting diversified business development [3] - The company is actively evaluating investment and merger opportunities that align with its strategic direction to enhance market share [5] Group 3: Financial Management - The company is committed to improving accounts receivable management, which has shown progress with a continuous decrease in accounts receivable balance [5] - A share repurchase plan was completed in March 2025, initiated in 2024, to address the stock price being below net asset value [5] Group 4: Product Development - The company has launched a new respiratory virus nucleic acid detection kit, which received medical device registration in May 2025, although sales have been limited so far [6] - The focus remains on enhancing the product line in pathogen diagnosis, cardiovascular disease diagnosis, and infectious disease diagnosis to improve market share [3]